The Enterprise Value as of September 2024 (TTM) for MacroGenics, Inc. (MGNX) is 168.08M

According to MacroGenics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 168.08M. This represents a change of -62.85% compared to the average of 452.43M of the last 4 quarters.

MacroGenics, Inc. (MGNX) Historical Enterprise Value (quarterly & annually)

How has MGNX Enterprise Value performed in the past?

The mean historical Enterprise Value of MacroGenics, Inc. over the last ten years is 620.95M. The current 168.08M Enterprise Value has changed 2.61% with respect to the historical average. Over the past ten years (40 quarters), MGNX's Enterprise Value was at its highest in in the March 2021 quarter at 1.62B. The Enterprise Value was at its lowest in in the September 2022 quarter at 150.68M.

MacroGenics, Inc. (MGNX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of MacroGenics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MacroGenics, Inc. (MGNX) Average Enterprise Value

How has MGNX Enterprise Value performed in the past?

The current Enterprise Value of MacroGenics, Inc. (MGNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MacroGenics, Inc. (MGNX) Enterprise Value vs. Peers

How is MGNX’s Enterprise Value compared to its peers?

MacroGenics, Inc.’s Enterprise Value is greater than Molecular Partners AG (-9786428.03), less than Mineralys Therapeutics, Inc. (509.22M), greater than AN2 Therapeutics, Inc. (4.27M), less than Pharvaris N.V. (676.59M), less than PepGen Inc. (253.77M), less than Monte Rosa Therapeutics, Inc. (284.72M), greater than PMV Pharmaceuticals, Inc. (41.69M), less than Tyra Biosciences, Inc. (966.91M), greater than Century Therapeutics, Inc. (149.62M), greater than Kezar Life Sciences, Inc. (30.94M), less than Nkarta, Inc. (361.36M), greater than NGM Biopharmaceuticals, Inc. (69.72M), less than Day One Biopharmaceuticals, Inc. (966.84M), less than Inozyme Pharma, Inc. (408.51M), less than Zentalis Pharmaceuticals, Inc. (281.22M), less than Syndax Pharmaceuticals, Inc. (1.43B), less than Protagonist Therapeutics, Inc. (2.40B), less than Edgewise Therapeutics, Inc. (1.54B), less than C4 Therapeutics, Inc. (433.52M), less than Cullinan Oncology, Inc. (864.04M),

Build a custom stock screener for MacroGenics, Inc. (MGNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MacroGenics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MacroGenics, Inc. (MGNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MacroGenics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.